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Summary The oestradiol (RE) and progesterone (RP) receptor levels were analyzed in 26 tumour fragments
(200-500mg) from breast cancer patients. After pulverization of tissue, one part was analyzed by the routine
dextran-coated charcoal (DCC) method and the other by a micromethod as follows: (i) cytosol incubation
using the DCC method but in the simultaneous presence of [3H]oestradiol and [3H]R5020 (ii) extraction of the
steroids bound to the receptor by precipitation with ethanol/TCA (iii) high pressure liquid chromatography
(HPLC) on a modular system, with a C185pm column and an elution by gradient mixture methanol/water.
The fractions were collected and the radioactivity counted.
The separation of oestradiol from R 5020 was rapid and complete. In addition dexamethasone was
separated by this system making possible triple measures of RE, RP and glucocorticoid receptors. A highly
significant correlation was obtained between the 2 methods: RE=0.996, P<O.OO1; RP r=0.975, P<0.001,
implying that the thresholds of positivity, i.e. for therapeutic decisions, remain unchanged. Simultaneous
measurement of RE and RP in a single needle biopsy is possible with this micromethod.
The measurement of steroid hormone receptors is
now a well-recognized common laboratory
procedure (McGuire, 1980). This is due to the fact
that breast cancer patients whose tumours contain
both oestradiol (RE) and progesterone receptors
(RP) are likely to respond in 75% of cases to
endocrine treatment (Osborne & McGuire, 1979)
whereas this proportion is only 10% for tumours
without such receptors (McGuire, 1980).
The most common measurement technique
involving the use of dextran-coated charcoal (DCC)
(McGuire, 1977) has certain intrinsic limits: a
separate cytosol fraction is required for
measurement of each receptor (Allegra et al., 1979).
This necessitates a relatively large quantity of
material that can only be obtained from a surgical
specimen. This constraint considerably limits the
applicability of receptor measurements, especially
for the study of tumours in situ, despite the fact
that the cellular heterogeneity of breast cancer is
well-known (Hawkins et al., 1977). Although
several authors have described the possibility of
measuring steroid receptors in needle biopsy
samples, it is difficult to evaluate several receptors
in a single sample (Poulsen et al., 1979; Delarue et
al., 1981). A recent method has been described for
the simultaneous measurement of both RE and RP
using different radioactive labels ([125I]-oestradiol
and [3H]-R5020). However, the problem inherent in
this method is the f emission by 125I, which makes
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this method difficult to utilize on a routine basis
(Thibodeau et al., 1981). A combination of the
DCC technique and high pressure liquid
chromatography (HPLC) has also been reported
(Magdalenat, 1979). We adopted this last technique
and attempted to determine its validity by
correlation with the routine DCC technique and
evaluation of its reproducibility.
Materials and methods
Collection ofsamples
The present study is based on the analysis of RE
and RP measurements obtained by two methods:
the method developed by us and the classical DCC
method of McGuire et at. (1977) realized for RP by
Pichon & Milgrom (1977) and used here on a
routine basis. Following histological examination,
fragments of the various tumours are divided into
two parts; one was used for the simultaneous
measurement of RE and RP receptors which
provides an immediate result for the clinician; the
other (200-500mg) was rapidly placed in liquid
nitrogen for later use in the comparative study.
Samples were selected on the basis of the initial
results in order to provide objective coverage of the
range of values generally observed. The
comparative study thus covered tumours from 26
patients. At the time of assay, tumour fragments
were assessed by the two methods: the classical
method used previously (in order to avoid a bias in
results caused by freezing and thawing) and the
micromethod described herein.
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Materials
Steroids: [3H] oestradiol (Sp. act. 111 Cimmol 1),
[3H] R5020 (Sp. act. 87Cimmol-1) and unlabelled
R5020 were purchased from New England Nuclear
(NEN), Boston, Mass. Diethylstilboestrol (DES)
was purchased from Sigma Chemical Co, St. Louis,
Mo., USA.
Buffer solution: Buffer R was: Tris/HCl 10-2M,
EDTA 10-3M, dithiothreitol (DTT) 0.5 10-3M,
Glycerol 10% (v/v); pH 7.4.
Dextran coated charcoal solutions: In Tris 10-2M
pH 8.0 0.5% Norit Charcoal, 0.05% Dextran T
70(DCC-A) or 2.5% Norit Charcoal, 0.25%
Dextran T 70.(DCC-B).
Preparation of cytosols: (a) For the usual method
(cytosol A) the tumour fragment stored in liquid
nitrogen was ground and pulverized under liquid
nitrogen using a Thermovac pulverizer (Ind Corp.,
Copiague, New York USA). The fine powder
obtained was then placed in 10vol buffer R. This
solution was homogenized using a Polytrom PT 10-
20 homogenizer (Brinkman Instrument. Inc.
Lucerne, Switzerland) at a speed setting of 6 for
3 x 5sec. intervals, in an ice-bath. The homogenate
was then centrifuged for 40min at 105,000g at 2°C
(Kontron Ultracentrifuge Unit, France).
(b) For the microassay (cytosol B), after
pulverization with the Thermovac pulverizer (only
one pulse), the fine powder (30mg) was completely
recovered with a small spatula (the tip of which has
been cooled in liquid nitrogen) and was
homogenized in 300pl of buffer R with a glass-
glass Potter homogenizer in an ice bath. The
homogenate was then centrifuged for 40min at
105,000g.
Methods
Usual assay procedure for RE and RP: For each
receptor assay, 100 1l of cytosol A were incubated
in duplicate in the presence of 100jl of solution of
tritiated hormone in buffer R with the following
final concentrations:
[3H]oestradiol: 10nM; 5nM; 1 nM
[3H] R5020: 20nM; 12nM; 3 nM
The same incubation was repeated for each
hormone in the presence of an excess of the
unlabelled hormone expressed as dry extract
(evaluation of non-specific binding). Thus, for
oestradiol, 100 times more DES was utilized for
each concentration, and for R5020 200 times more
unlabelled R5020 for each concentration.
Each test was conduced twice. Incubation lasted
16h at 2°C for RE and 2h at 2°C followed by 2h
at 2°C in the presence of 100M1 of a solution
glycerol/Buffer R (60/40, v/v) for RP. Upon
completion of incubation, 500 u1 of DCC-A
solution prepared 24h earlier were added to each
tube. For RE, incubation lasted 30min at 2°C; for
RP, 15min at 2°C under vigorous shaking. Tubes
were centrifuged for 20min at 2800g at 2°C and
500 1 of supernatant were counted for radioactivity
with 4.5ml of Picofluor 30 (Packard). Fifty-pl of
cytosol were used to determine protein
concentration using the Lowry method.
Calculation: The specific binding for each
hormone was determined by subtracting the non-
specific binding from the total binding. The RE
level considered was the mean of the two values of
specific binding obtained at the two saturating
concentrations (5nM and 10nM). RP level
determinations at the two saturating concentrations
(12nM and 20nM) were performed in the same
way.
Micro measurementfor RE and RP
Principle: The method involves 3 successive steps:
(i) incubation of the cytosol B and separation of
the free hormones by DCC (ii) precipitation of the
proteins and extraction of the hormones bound to
the receptors and (iii) separation of the hormones
by HPLC and measurement of the radioactivity of
the various fractions eluted.
Step I
Cytosol incubation was identical to the reference
method, except that [3H] oestradiol and [3H]
R5020 are co-incubated in the same 100pI aliquot
of cytosol. Only one concentration of labelled
hormone was utilized, i.e. [3H] oestradiol-7.5nM
(final concentration) and [3H] R5020 15nM (final
concentration). The non-specific tinding was
evaluated on another 100 u aliquot by repeating
the incubation in the presence of dry extract of
unlabelled hormones: 100 times more DES and 200
times more R5020. Incubation was carried out for
16h at 2°C, after which IOOj,l of the DCC-B
solution were introduced; following 15min of
incubation at 2°C, centrifugation was conducted for
20min at 2800g, 2°C.
Step 2
To 200pl of supernatant, 200M1 of pure ethanol and
20pl of an aqueous solution of 5% trichloracetic
acid were added, the tubes were placed on an
agitator for 2h at 2°C, then centrifuged for 20min
at 2800g at 2°C; the final supernatant was then
available for separation by HPLC.STEROID RECEPTOR MEASUREMENT 581
Step 3
The HPLC system included a 6000 A pump
(Waters Assoc., Milford, Ma. USA), a U6K
injector (Waters), a Model 440 absorbance detector
(Waters) fitted with a 254nm interferential filter
and a Data Module integrator (Waters).
Chromatographic separation of the steroids was
performed with a radial compression system (RCM
100, Waters), using Rad-Pak cartridges filled with
5pm microparticles of reversed phase C18 (Waters).
The elution was performed with a gradient system
methanol-water: buffer A, 72% methanol, 28%
double-distilled water, v/v; buffer B, 85% methanol,
15% double-distilled water, v/v. Initial conditions
100% A, 0% B; final conditions 0% A, 100% B.
Curve N° 8: 0-8min, curve No 11: 8-15min
(System controller, Waters). The flow rate was
2.5mlmin-1.
Unlabelled aliquots (100p1) of oestradiol (10-4M)
R5020 (5 x 10-5M) and dexamethasone (5 x 10-5M)
were first injected to identify the respective
retention times of these steroids at 254nm. The UV
detector and the recorder were then disconnected
and 100pl of supernatant from the extraction stage
were injected. Fractions (625p1) were collected at
the column outlet (one fraction every 15sec at a
flow rate of 2.5mlmin-1). Picofluor 30 scintillating
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fluid (4.5ml) was added, the tubes mixed well and
the radioactivity measured on a Packard LS
Spectrometer.
Calculation: For every peak corresponding to the
retention time of each steroid, the specific binding
was calculated by subtracting the peak related to
incubation in the presence of labelled hormone and
an excess of unlabelled hormone (non-specific
binding) from the peak for incubation in the
presence of labelled hormone only (total binding).
The results are expressed in fmolmg-' protein.
Results
Figure 1 corresponds to the chromatogram
obtained after injection of a mixture of unlabelled
(la) and labelled (lb) oestradiol, R5020 and
dexamethasone. The chromatographic separation
allows the identification of all 3 steroids. Figure 2
represents an HPLC profile allowing the
quantification of RE and RP following incubation
of a cytosol from a tumour specimen.
Comparison of the results obtained using the
reference method and our microassay is provided in
Figure 3 for the 26 cases examined. The correlation
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Figure 1 (a) HPLC separation of unlabelled hormones. 100.ul injected of the solution (A) dexamethasone
(5 x 0-5 M); (B) oestradiol (10-4M); (C) R5020 (5 x 10-5M). (b) HPLC separation of labelled hormones.
100p injected of the solution (A) dexamethasone (2x 10-9M) Sp.act.: 38Cimmol-1; (B) oestradiol
(0.5 x l0-9M) Sp.act.: 104CimmolV1; (C) R5020 (0.5 x 10-9M) Sp.act.: 87Cimmol-'.
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Figure 2 HPLC profile of the expected cytosols; (A) total binding; (0) non-specific binding.
Table I Correlation between the two methods
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cases Correlation Coefficient
Values RE 9 r=0.7269 P<0.05
<20fmolmg'- RP 10 r=0.8524 P<0.005
Values RE 17 r=0.9957 P<0.001
>20fmolmg-1 RP 16 r=0.9695 P<0.001
RE 26 r=0.996 P<0.001
All values RP 26 r=0.975 P<0.001
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Figure 3 Correlation between the 2 methods; (0) RE;
(V) RP; 26 cases.
of RE and RP values is as good for the extremes
(high and low values) as for all 26 values
considered altogether (Table I). Assessment of the
reproducibility of the microassay is given in Table
II. The coefficients of variation are satisfactory
(- 10%) although there is a slight tendency for
more marked dispersion for RP, in particular for
low values of the non-specific binding.
Discussion
The new method described here allows the
simultaneous measurement of steroid receptors in a
very small volume of cytosol. This has been made
possible by combining the classical DCC technique
with HPLC; the two additional steps are relatively
rapid because only 3 hours are required for
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Table II Intra-assay reproducibility of the micromethod
Results
Five measurements
ofthe same Means of
cytosol (cpm) Means+s.e. specific binding+s.e.
Total binding 172 185 171 mln=174+7.5
(T) 168 ND CV=4.3% iff(T-NS) = 146.8+7.7
RE Non-specific binding 27 28 28 m=27.2+ 1.9 =21.5+ 1.13fnolmg1
(NS) 29 24 CV=7% CV=5.2%
Total binding 574 619 565 mh=601.2+ 53.2
(T) 687 561 CV=8.8% fi(T-NS)=561.2+53.5
RP Non-specific binding 39 39 35 m=40+4.8 =82.1 +7.8fmolmg-
(NS) 48 39 CV=11.9% CV=9.5%
2 x 5 aliquots from one cytosol were used for the determination of the total and the non-specific
binding as described in Materials and methods.
ND =not determined.
CV=coefficient of variation.
extraction of the steroids bound to the receptors,
their separation by HPLC and their collection and
quantification.
This work represents a novel application of
HPLC which appears at present to be one of the
most valuable techniques in clinical biochemistry
(Elin, 1980). Connection of a continuous flux radio-
activity detector at the outlet of the chromatograph
may be used in order to allow automatic analysis.
This study was centred on the two main
receptors-RE and RP-since their evaluation has
proved useful in the clinical management of breast
cancer (Saez, 1981). However, the chromatographic
conditions we have established also permit
separation of dexamethasone from the two other
hormones, thereby increasing the method's
potential range of application. There is an inherent
problem in the inclusion of androgen receptor
measurements in this system because of the nearly
identical affinity of metribolone (R1881) for
androgen and progesterone receptors (Ojasoo &
Raynaud, 1978).
The highly satisfactory correlation observed
between the microassay and the DCC reference
method implies that the thresholds of positivity
established on the basis of the DCC method are not
changed by the microassay, and thus should not
alter the criteria used by clinicians in decision-
making. Reproducibility tests revealed coefficients
of variation close to 10%, indicating that the
microassay is reliable, and obviating replicate
measurements. Thus, with as little as 300pI of
cytosol, the protein concentration (50ul) and the
concentration of steroid receptors (2 x 100M1) could
be determined simultaneously. It is generally
admitted that the lower limit for the protein
concentration in cytosol is 1 mgml-1 if the DCC
technique is to be successful (Poulsen et al., 1979;
Leclercq et al., 1973). On this basis, samples of 20-
30mg can be analyzed by the microassay described
here. This weight corresponds to the quantity of
tissue obtained by a needle biopsy (Delarue et al.,
1981). This method is now used for the
simultaneous measurement of RE and RP on
biopsy specimens for in situ tumours in breast
cancer patients (unpublished data).
The heterogeneity of steroid receptors within a
mammary tumour is well established (Hawkins et
al., 1977; Poulsen, 1981). This variability can
probably be explained by the histological disparity
of mammary tumours (Gairard et al., 1981), which
means that it is advisable to couple each steroid
receptor measurement on a biopsy specimen with
microanatomical examination of a biopsy sample of
a nearby site. For advanced breast cancer there are
clinical indications preceding surgical intervention
by combined radiotherapy and chemotherapy
(Bruckmann et al., 1979). Consequently, the
biochemical characteristics of the cancer cells
removed during surgery are theoretically no longer
representative of the primary tumour prior to
treatment. It is thus preferable to measure RE and
RP on biopsy material prior to any treatment in
order to evaluate the degree of hormone
dependence. Certain studies suggest that RE status
in a given patient changes as the tumour progresses
(Osborne & McGuire, 1979) while other studies
have indicated that this status is not modified when584 G. MILANO et al.
biopsy samples of the primary tumour or of
subsequent metastases are examined (McGuire,
1980). To resolve this discrepancy, it would be
interesting to conduct a sequential study based on
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